850 860
1.03–2.48) per 10% increase for biopsy Decipher score
(
p
= 0.037).
4.
Discussion
In this study, we found that the Decipher genomic classifier
run on prostate needle biopsy specimens was able to
predict for distant metastasis and PCSM after radiation or
surgery. While the Decipher classifier was developed from
prostatectomy specimens, this is the largest study to
demonstrate its value based on biopsy samples and is the
first to show that it can predict outcomes in patients
treated with RP or RT as a first-line therapy.
The clinical implication of this study is that this genomic
classifier may be used at the time of diagnosis to help
provide accurate prognostic information for men with PCa
who are weighing their possible treatment options. Men
will know that the prognostic information can be valuable
whether they choose radiation or surgery.
[(Fig._3)TD$FIG]
Fig. 3 – Cumulative incidence curves for Decipher, Cancer of the Prostate Risk Assessment (CAPRA), and National Comprehensive Cancer Network
(NCCN) for prostate cancer-specific mortality (PCSM) endpoint. The dashed gray line represents the cohort average for PCSM risk.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 4 5 – 8 5 2
850